P&G to acquire 51.8 percent stake in Merck in India for Rs 1,290 crore

Published On 2018-04-21 05:00 GMT   |   Update On 2018-04-21 05:00 GMT

New Delhi: Procter & Gamble (P&G) will acquire 51.80 percent stake for Rs 1,289.88 crore in India listed drug firm Merck Ltd as part of a global deal under which it is taking over German firm Merck KGaA’s international consumer health business.


The global deal is for about 3.4 billion euro (Rs 27,677 crore) in cash. P&G will acquire Merck’s majority shareholding in Merck Ltd. (India) and make a mandatory tender offer to minority shareholders.


In a regulatory filing, Merck Ltd said Procter & Gamble Overseas India B.V and The Procter & Gamble Company have launched an up to Rs 647.53 crore open offer to acquire up to 4,315,840 equity shares of Merck Ltd, constituting 26 percent stake from public shareholders.


The open offer document said: “The acquirer (Procter & Gamble Overseas India B.V and The Procter & Gamble Company) has entered into a sale and purchase agreement…wherein it is proposed that the acquirer shall purchase from Emedia Export Company MBH, Merck Internationale Beteiligungen GmbH and Chemitra GmbH 8,599,224 equity shares…which constitutes 51.80 percent of the voting share capital.”


It further said sale of the equity shares held by the sellers is proposed to be executed at a “price of up to Rs 1,500 per fully paid up equity share aggregating to up to Rs 1,289,88,36,000 total for all equity shares held by the sellers payable as Euro equivalent in cash”.


The company also said under the open offer by P&G, up to 26 per cent of the fully diluted voting equity share capital will be acquired at a price of Rs 1,500.36 per share amounting to Rs 647.53 crore.


On the impact of the global transaction in India, Merck Ltd said: “As part of the transaction, Merck and P&G have agreed to a number of manufacturing, supply and service agreements.”

Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News